Similis Bio

Similis Bio is a biotechnology company that specializes in providing a comprehensive, full-stack solution for the development of biosimilar therapeutics. By offering ready-to-transfer programs that include high-titer cell lines, extensive analytical data, and robust process development, the company enables its partners to significantly reduce the time and technical risk associated with biosimilar market entry. Similis Bio focuses on high-value biologics across several therapeutic areas, including oncology, immunology, and ophthalmology. Following its acquisition by JSR Life Sciences in 2022, Similis Bio operates as a key component of JSR's broader biopharmaceutical services and manufacturing ecosystem.